This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aceragen 配当金

配当金基準チェック /06

Aceragen does not have a record of paying a dividend.

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$4.88
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

決済の安定と成長

配当データの取得

安定した配当: Insufficient data to determine if ACGN's dividends per share have been stable in the past.

増加する配当: Insufficient data to determine if ACGN's dividend payments have been increasing.

配当利回り対市場

Aceragen 配当利回り対市場

ACGN 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ACGN)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Biotechs)	2.8%
3年後のアナリスト予想 (ACGN)	n/a

注目すべき配当: Unable to evaluate ACGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

高配当: Unable to evaluate ACGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

株主への利益配当

収益カバレッジ: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

株主配当金

キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as ACGN has not reported any payouts.

This company listing is no longer active

Aceragen 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Price target decreased by 88% to US$17.00

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals completes acquisition of Aceragen

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought US$60k worth of stock

Independent Chairman recently bought US$101k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Price target increased to US$8.60

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

New 90-day high: US$5.40

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

President recently sold US$161k worth of stock

President notifies of intention to sell stock

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

New 90-day high: US$3.33

Idera Pharmaceuticals, Inc. Announces Board Changes

Idera Pharma names new operations chief

Earnings beat expectations

Idera Pharmaceuticals EPS misses by $0.37

New 90-day high: US$2.69

New 90-day high: US$2.68

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

New 90-day high - US$2.22

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06